Member Society Symposia

Type I Interferon Pathogenic Mediator and Therapeutic Target

Wednesday, June 14
12:45 PM - 4:45 PM

Sponsored By: 

Type I interferon comprises a family of proteins that play an essential role in anti-viral host defense and have many immunomodulatory activities. Altered regulation or sustained production of type I interferon is recognized to contribute to the pathologic consequences of chronic virus infections as well as some systemic autoimmune diseases, with systemic lupus erythematosus the prototype. This session will review recent data describing the cellular sources and molecular pathways responsible for production of type I interferon, the contribution of type I interferon to the immune dysfunction and tissue pathology in murine models of autoimmune disease and in chronic virus infection, and will describe potential therapeutic approaches for modulation of the pathogenic effects of type I interferon.

Chair:
Mary K. Crow, MD, Hospital for Special Surgery

Moderator:
J. Michelle Kahlenberg, MD, PhD, University of Michigan

Agenda:
12:45 p.m. Plasmacytoid Dendritic Cells - Regulation and Role in Autoimmune Disease Pathogenesis
Boris V. Reizis, PhD, Columbia University

1:30 p.m. Immune Dysfunction and Tissue Pathology Mediated by Type I Interferon: Studies in Murine Lupus Models
Dwight H. Kono, MD, The Scripps Research Institute

2:15 p.m. Type I Interferon in the Immunopathogenesis of Chronic Virus Infection
David G. Brooks, PhD, University of California, Los Angeles

3:00 p.m. - Coffee Break

3:30 p.m. Type I Interferons in Inflammatory Myopathies
Steven A. Greenberg, MD, Brigham & Women's Hospital

4:15 p.m. Opportunities for Therapeutic Targeting of Type I Interferon
Mary K. Crow, MD, Hospital for Special Surgery

Learning Objectives:


Assets

Type I Interferon Pathogenic Mediator and Therapeutic Target



Attendees who have favorited this

Send Email for Type I Interferon Pathogenic Mediator and Therapeutic Target